Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM336 in Autoimmune Cytopenias
NCT07083960Phase 1Recruiting
- Sponsor
- Lakefront Biotherapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of gamgertamig in autoimmune cytopenia, autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), sponsored by Lakefront Biotherapeutics. Primary endpoint: Safety and Tolerability at 12 weeks. Started Aug 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
autoimmune cytopeniaautoimmune hemolytic anemia (AIHA)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07083960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083960.